Liraglutide (Victoza/Saxenda) is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a hormone involved in appetite regulation, glucose balance, and metabolic signaling [1].
As a modified form of native GLP-1, liraglutide is engineered to resist rapid enzymatic breakdown, allowing it to remain active in the bloodstream far longer than the naturally occurring peptide.
This extended activity enables more sustained engagement of GLP-1 receptors, which are found throughout the:
GLP-1 plays a central role in coordinating how the body manages satiety cues, blood-glucose excursions, and nutrient utilization.
Liraglutide’s influence on weight regulation stems from its ability to activate GLP-1 receptors involved in:
A systematic review analyzed the efficacy and safety of liraglutide for weight loss in non-diabetic obese or overweight adults, by synthesizing outcomes from 11 RCTs and 1,328 total participants [2].
The average age of participants was 44.5 years, and the population skewed female (~ 79%). Liraglutide administration resulted in:
The pooled evidence shows that Liraglutide is effective in promoting clinically meaningful weight loss in non-diabetic overweight and obese adults.
Liraglutide’s extended engagement of GLP-1 receptors influences several pathways tied to metabolic efficiency and cardiovascular balance.
An RCT evaluated whether liraglutide 1.8 mg/day over 26 weeks improves diabetic cardiomyopathy in 49 type 2 diabetes (DM2) patients without known cardiovascular disease [3].
At the end of the intervention, Liraglutide showed:
Liraglutide reduced early LV diastolic filling and LV filling pressures, effectively unloading the left ventricle in patients with type 2 diabetes without cardiovascular disease.
Although small reductions in stroke volume and ejection fraction occurred, they remained within normal limits.
Although best known for its effects on appetite and metabolic regulation, liraglutide has also been studied for its influence on pathways relevant to bone and joint health.
GLP-1 receptors are present not only in metabolic tissues but also on osteoblasts, osteoclasts, and chondrocytes, suggesting a broader role in skeletal homeostasis.
A meta-analysis evaluated 17 animal studies to determine whether liraglutide improves bone pathology in animal models of osteoporosis [4]. Results showed that Liraglutide:
Liraglutide seems to improves osteopenia by:
These findings support liraglutide as a potentially valuable therapy for osteoporosis in diabetic patients, although higher-quality human studies are needed.
Liraglutide has also been shown to improve liver markers in mice models of non-alcoholic fatty liver. Significant reductions were noted in triglyceride content, fasting blood glucose, and LDL [5].
By extension of Liraglutide’s gastrointestinal effects, there has been evidence of gut microbiome modulation. Liraglutide increases levels of eubacteria like Bacteroidales and Akkermansia while reducing harmful bacteria like Bacteroides and Lachnospiraceae [5].
GLP-1 receptors are expressed in several brain regions involved in reward, mood regulation, and cognitive processing.
Liraglutide’s protection of brain insulin receptors has been associated with reversal of cognitive impairment and memory loss in mice [6].
These emerging lines of research reflect liraglutide’s broader physiologic relevance, positioning it as a valuable tool for understanding how GLP-1 agonists influence interconnected systems across the body.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Liraglutide is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes five independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 4-panel testing protocol: HPLC purity analysis, ESI-MS identity confirmation, LAL endotoxin screening, and amino acid analysis (for peptides >15 residues). Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders placed before noon PST, Monday–Saturday, ship the same day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and amino acid analysis where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 10+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.